Intellia’s in vivo CRISPR therapy lonvo-z meets Phase 3 HAELO endpoints, rolling BLA filing begins
Intellia Therapeutics disclosed on April 27, 2026, that its in vivo CRISPR gene-editing therapy lonvo-z, formerly NTLA-2002, met the primary endpoint and all key secondary endpoints in the Phase 3 HAELO trial for hereditary angioedema (HAE), and has begun a rolling BLA submission to the U.S. FDA. Three sources consistently point to positive Phase 3 results and view the program as a milestone for the in vivo CRISPR field, with only minor differences in trial details and emphasis.